NCT06993194 · NOT YET RECRUITING

Comparison of Haloperidol and Dexmedetomidine for Delirium and Agitation in ICU Patients With Traumatic Brain Injury

This trial compares two drugs — haloperidol and dexmedetomidine — for controlling delirium and agitation in ICU patients who have suffered a traumatic brain injury and are on a ventilator. It measures things like delirium severity, agitation levels, days on the ventilator, and ICU length of stay. This is a small, 40-patient study — an early-stage comparison trial, not a phase that establishes proof of effectiveness.

You may qualify if

  • Adults aged 18 years or older
  • Confirmed diagnosis of traumatic brain injury
  • Admission to the intensive care unit
  • Currently receiving mechanical ventilation
  • Richmond Agitation-Sedation Scale score between -5 and +4
  • At least 48 hours have passed since ICU admission

You're excluded if

  • Pre-existing neurological or psychiatric disorders (e.g., schizophrenia, bipolar disorder)
  • Known allergy or contraindication to haloperidol or dexmedetomidine
  • Significant hepatic or renal dysfunction
  • Pregnant or breastfeeding women
  • History of prolonged QT interval or other cardiac arrhythmias
  • Use of long-term antipsychotic or sedative medications before ICU admission

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-05-28

View full record on ClinicalTrials.gov

All APOE4 clinical trials